TXMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TXMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of TherapeuticsMD is: High Risk: High uncertainty.
For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Risk Assessment distribution charts can be found below:
* The bar in red indicates where TherapeuticsMD's Risk Assessment falls into.
TherapeuticsMD (NAS:TXMD) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of TherapeuticsMD's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Marlan D Walker | officer: General Counsel | 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431 |
Joseph Ziegler | officer: Principal Financial Officer | 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062 |
Michael C Donegan | officer: CAO and VP of Finance | 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507 |
Rubric Capital Management Lp | 10 percent owner | 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
Brian Bernick | director | 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
Mark A Glickman | officer: Chief Business Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Justin Hunter Roberts | director | C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
Tommy G Thompson | director | 7711 CARONDELET, ST. LOUIS MO 63105 |
Karen Ling | director | C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
Paul Bisaro | director | |
Angus C. Russell | director | C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jules A. Musing | director | 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711 |
David Efraim Rosen | 10 percent owner | 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
Collins Cooper C. | director | 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354 |
From GuruFocus
By PRNewswire PRNewswire • 07-10-2022
By PRNewswire PRNewswire • 07-06-2022
By Business Wire Business Wire • 07-13-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
By PRNewswire PRNewswire • 06-30-2022
By PRNewswire PRNewswire • 06-30-2022
By GuruFocusNews GuruFocusNews • 07-10-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By PRNewswire PRNewswire • 07-01-2022
By Business Wire Business Wire • 12-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.